Biosimilars Explained: The Investment Thesis Behind Pharma's Next Big Wave

Quick Facts

Note: Market-size estimates vary widely by source and methodology. Always verify against a company's latest disclosures before investing.

What You'll Learn

• Why biologic drugs created a US$300 billion "patent fortress" and how biosimilars finally crack it
• How a biosimilar is fundamentally different from a normal generic, and why that difference is the entire investment story
• How companies actually build a biosimilar, what it costs, and how they make money from it
• The global patent cliff that is about to release the largest wave of biologic competition in history
• Which companies worldwide, and specifically in India, are positioned to benefit

The Problem Biosimilars Solve

To understand biosimilars, you first have to understand why the world's most expensive medicines are so expensive.

For most of pharma history, drugs were small molecules: chemicals like paracetamol or atorvastatin, built atom by atom in a predictable, repeatable reaction. They are cheap to make, easy to copy exactly, and when their patent expires a genericGeneric DrugA copy of a brand-name drug with the same active ingredient, dosage form, and effectiveness, sold at a much lower price after the original patent expires.See all terms in the glossary manufacturer can reproduce the identical molecule for a fraction of the price. This is the engine that made India the "pharmacy of the world."

Then, beginning in the late 1970s, medicine changed. The invention of recombinant DNA technology in 1973 made it possible to engineer living cells to manufacture human proteins, and the biotech industry was born (Genentech was founded in 1976). The first product arrived in 1982, when synthetic human insulin became the first biologic drug ever approved. The real revolution came with monoclonal antibodies through the late 1990s and 2000s, the era that produced blockbusters like Rituxan (1997), Herceptin (1998), and Humira (2002).

These new therapies, the drugs that transformed cancer, rheumatoid arthritis, psoriasis, and diabetes, are biologics: large, complex proteinsProteinA large molecule built from chains of amino acids that fold into a precise 3D shape. The shape determines what the protein does, and it is dictated by the living cell that made it. Because that exact shape can't be reproduced by chemistry, protein-based drugs (biologics) can't be copied atom-for-atom — only approximated by a biosimilar.See all terms in the glossary grown inside genetically engineered living cells. A biologic molecule can be hundreds of times larger than a small-molecule drug, and its exact structure depends on the living system that produced it.

This complexity created two consequences that sit at the heart of the entire thesis:

First, biologics are extraordinarily effective. They became the best-selling drugs on earth. Humira (adalimumab) generated peak annual sales above US$20 billion. Keytruda (pembrolizumab) crossed US$29 billion in 2024. A single molecule can be a US$20 billion business.

But who actually owns these blockbusters? Understanding the originator (the innovator company that invented and patented the drug) is essential, because these are the giants whose monopolies biosimilar makers are trying to break.

Humira belongs to AbbVie, the US pharma company spun off from Abbott Laboratories in 2013. For years Humira was the single best-selling drug in the world, and at its peak it accounted for close to half of AbbVie's entire revenue, one of the most extreme cases of single-drug dependence in pharma history. Keytruda belongs to Merck & Co. (known as MSD outside the US and Canada), a 130-year-old American pharma giant. Keytruda, a breakthrough cancer immunotherapy, has grown to roughly 40 to 45% of Merck's total revenue.

Second, biologics were almost impossible to copy. You cannot "reverse-engineer" a protein grown in living cells the way you can copy a chemical formula. That meant that even after a biologic's patent expired, no one could make an identical version. The result was what economists call a natural monopoly: a US$500 billion fortress of biologic drugs that stayed expensive long after the patents that protected them had run out.

A biosimilar is the answer: a biologic medicine that is highly similarBiosimilarA near-copy of a biologic drug (made from living cells, like insulin or Herceptin). Unlike chemical generics, biosimilars cannot be chemically identical — they must prove 'similar' efficacy, making them harder and more expensive to develop.See all terms in the glossary to an already-approved reference biologic, with no clinically meaningful difference in safety or effectiveness. It is not an exact copy, because an exact copy is biologically impossible. It is a "similar enough" version, proven through extensive testing to behave the same way in patients.

Biosimilar vs Generic: Why This Distinction Is the Whole Story

Investors who treat biosimilars as "just generics for expensive drugs" miss the entire opportunity. The differences are what make the business model attractive.

The crucial line is the cost of entry. Because a biosimilar costs US$100 to 300 million and the better part of a decade to develop, only a handful of well-capitalised companies can even attempt it. High barriers to entry mean fewer competitors, slower price erosion, and more durable profit than the brutal commodity economics of small-molecule generics.

This is the paradox at the core of the thesis: the very difficulty that kept biologics monopolised for so long is now the difficulty that protects biosimilar makers from the price collapse that destroys generic margins. The hard part is the moat.

How Biosimilars Evolved: From Impossible to Inevitable

Biosimilars did not arrive fully formed. They needed regulators to invent an entirely new approval pathway, because the old generic rules simply did not apply to proteins grown in cells.

The most important recent development is regulatory, and easy to overlook. In late 2025 and into 2026, the US FDA proposed to eliminate many of the expensive comparative clinical efficacy studies that biosimilars previously had to run, and to simplify the path to "interchangeability" (the designation that lets a pharmacist substitute a biosimilar without the doctor re-prescribing). Industry analyses project this could cut development cost by as much as 50%, roughly US$20 million per program.

How a Company Actually Builds a Biosimilar

This is where the economics become concrete. Building a biosimilar is a manufacturing and regulatory feat, not a chemistry shortcut.

Step two and three are why this is a high-barrier business. For a biologic, the manufacturing process literally defines the molecule. A company without world-class bioreactor capacity and quality systems cannot make a biosimilar at all, no matter how much it wants to. This is the opposite of small-molecule generics, where the chemistry is in the public domain and the barrier is mostly regulatory paperwork.

It is also why contract manufacturingCDMO (Contract Development and Manufacturing Organisation)An outsourced pill factory that makes drugs for pharma companies. CDMOs earn stable, long-term contract revenue without the patent risk of a branded drug company.See all terms in the glossary and dedicated biologics capacity are strategic assets. A company that owns large-scale, regulator-approved biologics manufacturing can develop its own biosimilars and make money producing them for others. That dual role is central to the strongest players' business models.

The Patent Cliff: The Largest Opportunity in Modern Pharma

Everything above is the setup. This is the catalyst.

Between 2025 and 2030, an unprecedented wave of biologic patents expires. Industry estimates suggest that nearly 200 drugs, including around 70 blockbusters with over US$1 billion in annual sales each, will lose exclusivity, putting more than US$300 billion of revenue "in play." More than 60 major biologics alone come off patent across the US and EU in this window.

The Keytruda expiry around 2028 deserves special attention. As the single best-selling drug in the world, its loss of exclusivity is arguably the most valuable biosimilar opportunity ever created. Companies are already racing to position candidates years in advance, which is why partnerships and pipelines announced today are the right thing to watch, not current revenue.

The Global Competition

The global biosimilar market, roughly US$35 billion in 2025, is consolidating around a few large, well-capitalised players, exactly as the high-barrier economics would predict.

The top three (Sandoz, Pfizer, Amgen) together control roughly half the global market. Europe is the most mature region at around 37% of the market; Asia-Pacific is the fastest-growing. South Korea's Samsung Bioepis and Celltrion have shown that scale manufacturing plus regulatory expertise can build a global biosimilar franchise from outside the traditional Western pharma centres, a template that matters enormously for the India thesis.

India's Biosimilar Play: Who Is Positioned to Benefit

This is where the thesis becomes most interesting for an investor analysing Indian pharma.

India has a structural advantage that mirrors its dominance in small-molecule generics: low-cost, high-quality manufacturing at scale, combined with deep regulatory experience in Western markets. But there is a critical difference. In generics, India competes with everyone. In biosimilars, the barriers are so high that only a handful of Indian companies can play, which means less internal competition and more durable positioning for the winners.

By December 2025, India had approved roughly 146 biosimilar products domestically, one of the largest counts in the world. But the domestic market is only the training ground. The real prize is the US and Europe.

The "big five" of Indian biosimilars, Biocon, Intas, Dr Reddy's, Zydus and Lupin, have captured the bulk of Indian biosimilar approvals and launches. What separates the leaders from the followers is vertical integration: owning the cell-line science, the manufacturing, and the global commercial footprint. Biocon Biologics is the only Indian company that owns all three at global scale, which is why it is treated as the bellwether for the entire India biosimilar thesis.

The Investment Thesis: Bull and Bear

The Bull Case

1. A historic, mechanical catalyst. Over US$300 billion of biologic revenue loses patent protection by 2030. This is not a forecast of demand, it is a scheduled legal event. The molecules will face competition; the only question is who supplies it.

2. High barriers protect margins. Unlike generics, biosimilars do not collapse to commodity prices. Fewer competitors and modest discounts mean a successful product can earn for years.

3. India's structural cost and scale advantage. The same forces that made India the pharmacy of the world apply to biosimilars, but with far fewer domestic competitors able to clear the barrier.

4. Regulatory tailwinds. 2025 to 2026 FDA reforms are cutting development cost and time, making more molecules economically viable and speeding time to market.

5. Optionality on the giants. The Stelara, Eylea, Prolia and especially Keytruda cliffs offer multi-hundred-million-dollar opportunities per molecule for companies that position early.

The Bear Case

1. Lower barriers cut both ways. The same cost reforms that widen the opportunity also erode the moat. If development gets cheap enough, biosimilars start to look more like commodity generics, with the price erosion that implies.

2. Capital-intensive and back-ended. Companies spend heavily for years before revenue arrives. Returns depend on execution across science, manufacturing, litigation, and commercial contracting, any of which can slip.

3. Manufacturing and FDA risk. Biologics plants face intense regulatory scrutiny. A compliance failureImport AlertThe most severe FDA action: blocks all shipments from a specific plant into the US market. Companies can take 12–36 months to get an Import Alert lifted.See all terms in the glossary can wipe out a launch window worth hundreds of crores.

4. Payer and pricing pressure. In the US, the rebate-and-formulary system can blunt biosimilar uptake; some early biosimilars gained share far more slowly than expected.

5. Concentrated outcomes. For most players, the thesis rests on a small number of high-value launches. Miss on one or two, and the economics change materially.

How to Evaluate a Biosimilar Company

When you analyse any company claiming a biosimilar opportunity, look past the press releases and check these five things:

Vertical integration. Does it own the cell-line science, large-scale manufacturing, and a global commercial footprint? Owning one without the others limits the value it can capture.

Pipeline depth and timing. How many molecules, targeting which originators, launching in which years? A pipeline aligned with the 2025 to 2030 cliff (Stelara, Eylea, denosumab, Keytruda) is worth more than one chasing already-crowded targets like Humira.

Manufacturing capacity and compliance. Tour the FDA inspection history. Clean biologics plants are a prerequisite, not a bonus. A Warning Letter is a thesis-breaker.

Revenue quality. Is biosimilar revenue real and recurring (US/EU launches with payer contracts) or is it still "pipeline optionality" that may never convert?

Partnership structure. Many Indian players partner with Western distributors (the Alvotech, Viatris, and similar deals). Understand who keeps the economics, the developer or the distributor.

Key Takeaways

• Biosimilars solve a specific problem: biologics stayed monopolised even after patents expired, because no one could copy proteins grown in living cells. Biosimilars create the first real competition.
• A biosimilar is "highly similar," never identical, and that distinction is the whole investment story: it costs US$100 to 300 million and 7 to 8 years to build, which keeps competitors few and margins durable.
• The business model rewards scarcity of competition, not cheapness. Modest discounts on multi-billion-dollar originators make a single biosimilar a major business.
• A scheduled patent cliff puts over US$300 billion of biologic revenue in play through 2030, with Keytruda around 2028 as the single biggest prize.
• Globally, Sandoz, Pfizer and Amgen lead; in India, Biocon Biologics is the integrated leader, with Dr Reddy's, Intas, Zydus, Lupin, Cipla and Aurobindo building behind it.
• The opportunity is large and the catalyst is certain, but the value is back-ended to FY27 to FY32 and the risk is entirely in execution and compliance.

Frequently Asked Questions

What is the difference between a biosimilar and a generic?

A generic is a chemically identical copy of a small-molecule drug, cheap and fast to make, which is why generics launch at 80 to 90% discounts and face dozens of competitors. A biosimilar is a "highly similar" version of a biologic, a large protein grown in living cells that cannot be copied exactly. Biosimilars cost US$100 to 300 million and 7 to 8 years to develop, launch at more modest 15 to 50% discounts, and face far fewer competitors. The barriers to entry are the entire reason biosimilars are a more attractive business than generics.

Why can't biologics simply be copied like generics?

Because a biologic's structure depends on the living cells that produce it, and that manufacturing process cannot be perfectly reproduced by anyone else. Two batches made by different companies, or even the same company, are never atom-for-atom identical. This is why regulators created a separate "biosimilar" category: instead of proving the copy is identical, the maker must prove it is similar enough that there is no clinically meaningful difference in safety or effectiveness.

Which Indian company is the leader in biosimilars?

Biocon Biologics is widely regarded as India's biosimilars leader and its only globally integrated pure-play. It reported around Rs 9,000 crore in FY25 revenue, had four biosimilars each selling over US$200 million, and has gone direct-to-market in the US and Europe after acquiring Viatris's biosimilars business. Dr Reddy's, Intas, Zydus, Lupin, Cipla and Aurobindo are also building biosimilar franchises, but none yet matches Biocon's vertical integration and global scale.

What is the biosimilar patent cliff?

It refers to the wave of biologic drugs losing patent protection between roughly 2025 and 2030, an estimated 200 drugs (including around 70 blockbusters) representing over US$300 billion in revenue. As each biologic loses exclusivity, biosimilar competitors can enter. Humira's cliff arrived in 2023, Stelara and Eylea in the mid-2020s, and Keytruda, the world's best-selling drug, is expected around 2028. This scheduled, mechanical loss of monopoly is the central catalyst behind the biosimilar investment thesis.

Are biosimilars safe and as effective as the original?

Yes. To be approved by regulators such as the FDA, EMA, or India's CDSCO, a biosimilar must demonstrate through rigorous structural, laboratory, and clinical testing that there is no clinically meaningful difference from the reference biologic in safety, purity, and effectiveness. Biosimilars have been used at scale in Europe since 2006 with strong real-world safety records. This is general educational information, not medical advice; treatment decisions should always be made with a qualified clinician.

What to Read Next

• From Lab to Pharmacy: How India's Drug Industry Really Works
• Drug Patents, Generic Moats, and India's Global Edge
• How to Evaluate a Pharma Stock
• AI, Protein Folding, and the Future of Drug Discovery
• Sun Pharma: Business Model, Moat, and Investment Case
• Dr. Reddy's: The Export-Led Generic Powerhouse